Omnicell (FRA:OC9) Other Long Term Assets: €161 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OC9 Omnicell Inc FRA:OC9
78 GF Score
Price €27.80
GF Value €32.54
! 6 Warning Signs
View Full Analysis

What is Omnicell Other Long Term Assets?

Omnicell FRA:OC9 -1.42% 78 Other Long Term Assets is €161 Mil as of Jun. 2026. GuruFocus rates FRA:OC9 with a GF Score™ of 78/100 and a GF Value™ of €32.54. The stock has 6 warning signs investors should review.

Omnicell's other long-term assets for the quarter that ended in Jun. 2026 was €161 Mil.

Omnicell's quarterly other long-term assets increased from Dec. 2025 (€169 Mil) to Mar. 2026 (€171 Mil) but then stayed the same from Mar. 2026 (€171 Mil) to Jun. 2026 (€161 Mil).

Omnicell's annual other long-term assets increased from Dec. 2023 (€138 Mil) to Dec. 2024 (€179 Mil) but then declined from Dec. 2024 (€179 Mil) to Dec. 2025 (€169 Mil).

Omnicell Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Omnicell's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omnicell Other Long Term Assets Chart

Omnicell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 113.08 130.23 137.67 179.37 169.22

Omnicell Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 163.87 165.19 169.22 170.95 160.85
FRA:OC9
78GF Score
Omnicell Inc FRA:OC9
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Omnicell Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of €161 Mil mean?
Omnicell (FRA:OC9) has a Other Long Term Assets of €161 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Omnicell and its competitors.
Is Omnicell's Other Long Term Assets too high?
Omnicell's current Other Long Term Assets is €161 Mil. Overall, Omnicell has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Omnicell's Other Long Term Assets compare to SDGR and OMDA?
Omnicell's Other Long Term Assets of €161 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Healthcare Providers & Services company?
A good Other Long Term Assets depends on the Healthcare Providers & Services industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Omnicell and its competitors. Omnicell's current Other Long Term Assets is €161 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omnicell stock overvalued right now?
Omnicell (FRA:OC9) has a current Other Long Term Assets of €161 Mil. The stock's GF Value™ is €32.54, compared to a current price of €27.80 — trading 14.6% below its estimated fair value. The current Other Long Term Assets is €161 Mil. Omnicell's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Omnicell (FRA:OC9), the current Other Long Term Assets is €161 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Omnicell (FRA:OC9) Overvalued in 2026?

Based on GuruFocus' analysis, Omnicell stock appears to be undervalued. The current stock price of €27.80 is trading 14.6% below its estimated GF Value™ of €32.54.

Key valuation signals for FRA:OC9:

  • Other Long Term Assets: €161 Mil
  • GF Value™: €32.54 vs. price of €27.80 (14.6% below fair value)
  • GF Score™: 78/100 with 6 warning signs

No single metric tells the full story. See the FRA:OC9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Omnicell Business Description

Other Exchanges OMCL:USAOMCL:Mexico
Address 4220 North Freeway, Fort Worth, TX, USA, 76137
Omnicell Inc. is a US-based healthcare technology company that provides medication management and supply chain automation for healthcare providers. Its product portfolio includes automated dispensing cabinets, central pharmacy automation systems, sterile compounding robots, and medication adherence packaging, along with software platforms for inventory control, analytics, and patient engagement. These offerings serve hospitals, health systems, retail pharmacies, long-term care facilities, and other care settings, helping pharmacists and nurses reduce manual tasks and improve medication safety. Omnicell generates revenue primarily through the sale and lease of hardware and software systems, combined with recurring service, maintenance, and subscription-based software fees. The company's largest market is the United States, which accounts for the majority of its revenue, with additional operations in Europe, the Middle East, Asia-Pacific, and other international regions.
78GF Score

Get the complete analysis for FRA:OC9

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.80
Price
€32.54
GF Value